



Supporting arthritis research, education
and patient engagement



**ANNUAL
REPORT
AND
ACCOUNTS**
31 March 2024

**Company Registration
Number 02908933
Charity Registration
Number 1040650**

Trustees' Annual Report for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Contents	Page
Charity information	1
Trustees' Annual Report	2
Statement of directors' responsibilities	12
Independent Examiner Report	14
Funds Statements:-	
Statement of Financial Activities	16
Prior Year statement	17
Statement of total recognised gains and losses	18
Income and Expenditure account	19
Balance sheet	20
Notes to the accounts	22

Trustees' Annual Report for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Charity information

The Trustees present their Report and Accounts for the year ended 31 March 2024, which also comprises the Directors' Report required by the Companies Act 2006.

The charity name

The legal name of the charity is:- Bath Institute for Rheumatic Diseases. The charity is also known by its operating name, BIRD.

The charity's areas of operation and UK charitable registration.

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1040650. The charity does not operate in any overseas jurisdictions.

Legal structure of the charity

The charity is constituted as a company limited by guarantee, registered under the Companies Acts. The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 24 November 2020.

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation. The trustees are all individuals.

The principal operating address, telephone number, email and web addresses of the charity are:-

Department D1
Wolfson Building, Royal United Hospital Bath,
BA1 3NG
Telephone 01225 336363

BIRD@birdbath.org.uk www.birdbath.org.uk

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

The Trustees in office for the period covered by the report:

Chris Johns
Dr Amanda Mackenzie
Prof Neil McHugh
Prof Bernie Morley emeritus - **Chair**
Shane O'Reilly
Prof Raj Sengupta
Jim Sherwin
Linda Snelus
Dr William Tillet

Trustees' Annual Report for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Objects and activities of the charity

Bath Institute for Rheumatic Diseases (BIRD) is an incorporated charity. Its objectives, as set out in the Memorandum and Articles of Association, are to relieve sickness and to promote and advance medical knowledge with particular reference to rheumatic diseases; and to undertake research in relation thereto and to publish the useful results of such research. BIRD funds research and education into all areas of rheumatology and all types of bone and joint disorder.

Strategy

We continue to follow our new strategy with the central purpose of balancing reliance on investment performance over the long term with more grant and donor fundraising, which in turn requires a raised profile and clearer articulation of impact.

A recent stakeholders survey highlighted the progress we have made with comments such as **"BIRD is now more outgoing and focused on engagement and education of staff and patients"** and **"overall I think that the organisation now reaches far more people than in the past and the number research grants given has increased"**.

Research Collaboration
Encouraging Partner Efficient
Patient Interaction Patient Engagement
WHAT DO Innovative Research active
OUR STAKEHOLDERS Friendly
Podcasts **THINK OF BIRD?**
Supports clinicians and patients
Patient oriented organisation
Great Resources Charity

Highlights

- **Shortlisted for Charity of the Year in the South West Business Awards**
- **Reaching the 20,000 milestone in listens to BIRD podcasts for patients**
- **BIRD attending the British Society of Rheumatologists conference for the second time to highlight our work**
- **BIRD organising the second Research Showcase event in Bath**
- **BIRD producing six new videos for use in the reception area of the Royal National Hospital for Rheumatic Diseases**
- **BIRD being placed on the Chancellor's Roll of Honour at the University of Bath (see below)**



We finish the financial year with £1,791,638 in funds, up from £1,676,599 at the same point last year, reflecting good growth in BIRD's investment funds since income totalled £106,886 but expenditure £238,682. In total BIRD awarded £66,406 in grants and bursaries to clinician researchers and early career researchers and spent £59,054 on patient and public engagement.

Trustees' Annual Report for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Grants awarded for research

BIRD funds research projects in rheumatic diseases which:

- **Help to promote and advance medical knowledge**
- **Improve treatments for patients**
- **Encourage collaboration between clinicians and research scientists**
- **Supports the next generation of researchers into bone and joint diseases**

The focus is on pump prime funding for smaller projects, undertaken in or from Bath for the benefit of patients worldwide.

The guideline for grant amounts is up to £20,000 (but greater amounts may be considered) that would be ideally suited to pilot studies, preliminary research, tests of clinical effectiveness or would enable other grants to be made for research.

It aims to promote and advance medical science, pump-priming research, help researchers in the early stages of their careers, help clinicians to be research active, encourage collaborations between clinicians and research scientists, and ensure patients are involved in research.

Projects funded by BIRD are often highly collaborative, with researchers and clinicians working together to address challenges in rheumatic diseases.

Since 2016 BIRD has funded over 26 projects, with over 600 patients involved in a meaningful way, helping to advance medical science, with grants generating at least 20 academic publications so far.

In total, £63,551 for research was awarded

£19,950 to Dr Jessica Ellis for a project about the Utility of a novel imaging biomarker for the identification of excess cardiovascular risk in auto-immune rheumatic diseases.

We hope this project will improve the identification of cardiovascular disease in rheumatology patients. It will use existing CT scans from lupus and scleroderma patients, and measure inflammation on these scans. This project will then see whether it can identify increased cardiovascular risk using existing tools. It will also use a large national database of scans, to see whether rheumatology patients are more likely to have this inflammation.

£19,953 to Dr Amanda Mackenzie for a project promoting the regression of angiogenesis in the pathology of rheumatoid arthritis. Rheumatoid arthritis is a common disease, affecting more than 400,000 in the UK. Blood vessels grow into joints during the progression of the disease. This growth makes the damaging inflammation worse and increases joint pain. This project aims to improve treatments for patients with rheumatoid arthritis and promote collaboration between clinical and research scientists.

£2720 to Fionnula McMorow For knowledge exchange of IP-MS method at KU Leuven. As part of a PhD this project involves using and adapting highly specialised laboratory techniques to try and find new autoantibodies in the blood of children with rare rheumatic diseases called myositis and systemic sclerosis,

Trustees' Annual Report for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

£20,000 to Dr Joseph Page for assessing the Vascular Endothelium in Systemic sclerosis associated Pulmonary hypertension to improve Early and Rapid diagnosis (VESPER)

Pulmonary arterial hypertension (PAH) and progressive fibrotic interstitial lung disease (ILD) are common and sadly fatal complications of Systemic Sclerosis. The study will invite patients with and without systemic sclerosis to provide a blood test. The researchers will compare the results between patients with and without systemic sclerosis. It will also look to see whether these tests match with right heart catheterisation results in patients who have this test done as part of their routine care. If we can improve our understanding of blood vessel damage in systemic sclerosis, it may help us to predict which patients are more at risk of developing PAH, and commence timely treatment. It may help provide more accurate non-invasive tests to detect PAH.

£928 to the RNHRD Research Nurses for a Laptop

Bursaries

Building on the recent success of early career researchers BIRD awarded **£2755** for bursaries to attend BSR and EULAR, and the World Congress on Osteoporosis in early 2024.

This is to encourage health professionals based in the Royal National Hospital for Rheumatic Diseases (RNHRD) to attend these key national and international conferences as part of BIRD's mission is to encourage clinical staff to be research-active and to maintain the RNHRD's reputation for research excellence.



"The British Society for Rheumatology (BSR) conference, is a key event in my work calendar. Every year I meet new people and develop contacts with colleagues around the UK. Lots of action points and things for us to review and develop further in our service here in Rheumatology Therapies".

"Thanks so much for BIRD support to attend my first BSR meeting. It was great to hear from leading clinicians and researchers in the field of AxSpA and axial PsA, and also be able to attend other sessions covering a range of the rheumatology field. Quite mind-blowing at times".

My experience at BSR was fabulous. I was able to discuss complex cases with my colleagues and also saw many interesting educational abstracts. This gave me further ideas on how to innovate our system but also enabled me to enhance my research work".

Trustees' Annual Report for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

For the second time BIRD took a stand at the annual British Society for Rheumatology Conference in Manchester to showcase the Patient Engagement programme. This was to promote and network for further patient engagement opportunities.

BIRD led and organised the RNHRD's second Research Showcase Event at the Bath Royal Literary and Scientific Institute in March 2024 together with Royal United Hospital Bath, and the University of Bath.

Five Consultants and early career researchers from the RNHRD gave talks on their research and showed 10 research posters for 60 members of the general public. The feedback was again very positive and BIRD plan to make the Research Showcase an annual event.



"All of the talks were engaging. It is wonderful to listen to our doctors so full of passion for their specialism and wanting to provide the best for their patients".

"I found the talks all very informative, very interesting and very beautifully presented by the professionals. I am very grateful to have attended and would love to come to other similar events. I hope that there will be more".

"We really enjoyed the speakers and their enthusiasm into their specialist research. It was wonderful to see their passion and desire to find out more around their specialism and their desire to pass on their findings for those in their care now and in the future".



Trustees' Annual Report for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

BIRD's education programme for Healthcare Professionals

BIRD organised a wide-ranging programme for the continued education and training of healthcare professionals, working closely with a range of health and education providers, including the Royal United Hospital for Rheumatic Diseases, the University of Bath and the Bath GP Education and Research Trust. The programme was attended by Consultants, Clinical Staff, Academic and Clinical Researchers, GPs, Nurse Practitioners and Primary Care Healthcare Professionals.

BIRD provided the administration support including the accreditation and sponsorship where necessary, for **educational events reaching 415 healthcare professionals**. Each of the training sessions was **approved for accreditation by either the Royal College of Physicians or the Bath GP Education & Research Trust** (depending on whether the attendees came from primary or secondary care) which enabled them to gain continuing professional development credits.

The programme for 2023/24 included the following events:

One Rheumatology Research @ Bath meeting was held, bringing together researchers at the University and clinicians at the hospital to update one another on two new projects at a time.

Two Bath & Bristol Bone meetings were held in May and November 2023 for consultants and clinical staff.

The South West Axial Spondyloarthritis Group was held in November 2023 for consultants and clinical staff.

Two South West CTD & Vasculitis meetings were held in March & September 2023 for consultants and clinical staff.

Two Primary Care Rheumatology Update afternoons were held in April 2023 and March 2024 for GPs, Nurse Practitioners and Primary Care Healthcare Professionals.

Knowledge Exchange with Stoke UHNM NHS Trust & RNHRD – BIRD provided the organisation and admin support for the Stoke visit to Bath. Over the two-day event each Trust shared their practices and procedures for the Management of Spondyloarthritis.

Qualitative feedback collected from some of the sessions showed that participants rated talks either **'excellent'** or **'good'** with most comments finding the training "helpful" and a useful update;

"The hybrid option for meetings is really valuable and great to see so many attendees online. Great selection of speakers at these events, with fantastic external speakers. Good to see some younger investigators given chance to present and raise their profiles within the region."

"These are always great meetings - all presentations excellent and very useful discussion. The meeting was very well organised and chaired."

The Education Programme was led by Dr Andrew Allard, consultant rheumatologist, and Fran Staples, Senior Administrator BIRD.

Trustees' Annual Report for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

The Patient and Public Engagement Programme

The Programme vision is to **help more patients to be involved in research and deepen their understanding of Rheumatic Diseases**, the latest research and treatment. With the twin aims of:

1. Patients have a deeper knowledge of Rheumatic Diseases, helping to lessen anxiety and increase confidence to self-manage and communicate with their healthcare professionals

2. Patients are involved in research, helping to inform and share the patient perspective with researchers to ensure the aims are true to need

Led by patient engagement expert Mel Brooke and supported by Fran Carroll, **the programme has continuously evolved and developed around patient audience needs**. It provides **opportunities** for them to **connect, learn and share** through a flexible and innovative mix of media.

Podcasts - covering a range of rheumatology conditions, these **now reach thousands of patients and their families**, across the country (and beyond) which we promote heavily on social media.



Over the year Mel Brooke produced another **10 new podcasts** bringing the **library to 58** and achieving an amazing **total of 23,559 listens**.

New topics covered were **Gout, Myositis, new BSR guidelines, Psoriatic Arthritis (PsA), updated NICE guidelines on Osteo Arthritis Nutrition, Pain and Mental Health**

Webinars - were developed, providing **live events online** that **give patients access to consultants** and experts' presentations and the opportunity to ask questions. **577 patients attended six webinars** on Axial Spondyloarthritis, PsA and Osteoporosis.



"A very useful webinar covering a great deal of research explained in a digestible way."

"I've learnt some things today which have completely changed my view on my disease activity and care alongside that."

"So grateful for these webinars, the knowledge shared, and opportunity to ask questions."

100% of patients who attended the Osteoporosis webinar would recommend others to attend.

Trustees' Annual Report for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Research - patients tell us they are keen to 'give back' and get involved in research, mainly through taking part in surveys and questionnaires circulated but also through focus groups, workshops and other participation. **Over 188 patients were involved in research during the year.**

Patient Research Panel – 28 committed enthusiasts provided feedback on survey design and research opportunities to academic and clinical researchers during the year

Some highlights of the work involving patients in research over the last year include

- *helping the RUH Research Database Team to engage patients to help test an online survey designed to support the Rheumatology Advice Line.*
- *supporting a researcher to share a call for people to participate in a Fibromyalgia Focus Group*
- *guiding the patient research panel to lay review a Patient Information Leaflet for a new tissue bank relating to Systemic Autoimmune Rheumatic Diseases (SARDs)*
- *helping a researcher find participants for a PsA workshop in biologics, set up and co-host the online evening workshop, help capture and summarise the qualitative data input.*
- *helping to share a survey to gather patient opinions and, later, help again to find participants to attend a workshop (research to develop the concept for a new tool to support hand exercise and self-manage medications in RA)*
- *helping the Rheumatology Research Team at the RUH to find volunteers to participate in a research study day in PsA*
- *helping a historical writer find people to share lived experience of Lupus for research for their book. WW*


- *helping share an opportunity for people with PsA to participate in a project aimed at helping improve the patient and public engagement in clinical trials.*
- *helping to find patients to participate in workshops about PIFU (Patient Initiated Follow Up)*
- *helping to review patient information documents for an observational study on use of a medication in axSpA and PsA (through the Patient Research Panel)*
- *helping a researcher shape the questions for a research survey in fatigue and exercise in axSpA and, later, share it with the BIRD patient network to gather patient insights.*

Awareness raising

The reach of BIRD continued to expand through ongoing investment in Facebook, Instagram, X and LinkedIn, with over **334,000 people getting the opportunity to see a BIRD advertisement for podcasts**. BIRD's subscriber database grew by **34%** across Twitter, Facebook, Mailchimp and LinkedIn.

Particular success was achieved in **celebrating the 20,000 listens to podcasts** milestone, achieving good coverage in local press and BBC radio. This led to BIRD being nominated in the South West Business awards as Charity of the year.

BIRD also produced **six information videos to be used in the reception at the RNHRD**



Trustees' Annual Report for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

–these covered various topics including an introduction to the RNHRD, Biologics and a short introduction to the research department's work.

BIRD was also delighted to be **placed on the Chancellors Roll of Honour at the University of Bath**, this recognises the support BIRD has given the University over the years.

Effort spent in seeking to attract **grants** from pharmaceutical companies for the **Patient Engagement programme** was rewarded with **£22,000 in grants and sponsorship from Eli Lilly and Company and UCB**. This was largely due to the **excellent performance of the podcasts** and advertising them widely on social media, which attracted thousands of listeners.

The **following people and trusts gave significant donations and legacies for which BIRD is very grateful**, and their names were **added to the Benefactors Board**, recently moved to the entrance of the Royal National Hospital for Rheumatic Diseases

Erika Wiesenmueller-Potter and Barry Potter
Mary Dixon
Medlock Charitable Trust
Hospital Saturday Fund
Renishaw

Many others made donations to BIRD over the year, often after reading news or research and developments in BIRD's newsletter. **Thank you to all for the vital support.**



The main achievements and performance of the charity in terms of public benefit

The **total amount of grants and bursaries** awarded for research into rheumatic diseases was **£66,406**

415 professionals attended BIRD training sessions, meetings and events for consultants, clinicians, healthcare professionals, researchers and academics.

100% of patients who attended the Osteoporosis webinar **would recommend others to attend future webinars**

15 opportunities to participate in research, were offered to patients, **26 members** of the patient research panel **responded to 5 new research opportunities**.

90% of the 60 attendees to the Research Showcase said they were **more likely to get involved in research**.

188 Patients involved in research

Awareness raising continued to grow through **advertising, e-newsletter engagement** and stakeholder relations with the University and the Hospital.

34% growth in subscribers

BIRD recruited new committee members to the finance and research committees.

Overall, the charity's beneficiaries: scientific academia and patients, carers and their families benefitted from better understanding of rheumatic diseases and their treatment, thereby contributing to the alleviation of suffering.



Structure, governance and management of the charity

The governing body is the Council of Management made up of 9 trustees. The chair is now Professor Bernie Morley emeritus, the Council of Management meets triannually.

Three committees report to the Council of Management.

There are the triannual **Finance Committee**, chaired by Jim Sherwin, members are Dr Linda McHugh, Chris Johns, Linda Snelus and new member Bernard Fairhurst; the biannual **Research Committee**, chaired by Professor Bernie Morley emeritus, members are Ben Hutchinson, Dr Amanda MacKenzie, Professor Neil McHugh, Dr Sarah Skeoch, Dr Paula Smith-resigned and has been replaced by Dr Abbie Jordan, Dr Theresa Smith, Frank Sweeting and Dr Sarah Tansley; and the triannual **Education & Engagement Committee**, chaired by Shane O'Reilly, members are Dr Andrew Allard, Patricia Mattinson and Jessie Naish. All committees are supported by relevant contract staff in attendance.

	2024 £	2023 £
Net income	115,039	(142,906)
Unrestricted Revenue Funds available for the general purposes of the charity	1,754,967	1,631,034
Designated Revenue Funds	18,478	26,886
Total Unrestricted Funds	1,773,445	1,657,920
Restricted Revenue Funds	18,193	18,679
Total Funds	1,791,638	1,676,599

The Finance Committee, on behalf of Council ensured BIRD's investments maximised the funds available for furthering BIRD's charitable objectives. To this end costs were scrutinised and investment performance was reviewed quarterly alongside the operational management accounts.



BIRD's reserves policy is to

- hold 12 months of planned expenditure as readily accessible reserves to ensure continued financial security and to provide for contingencies; and,
- retain sufficient in investments to maintain its grant giving capacity and educational programme.

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

The aim of the investment strategy is to provide sufficient income and capital growth to provide a total return above the rate of inflation, over time, such that a proportion can be used for research or to support the charitable aims, whilst at the same time maintaining the real value of the portfolio. The objective is a 'balanced' return between income and capital, at medium risk over a time horizon of ten years plus.

Both capital and income may be used at any time for the furtherance of the charity's aims and therefore the portfolio is managed on a total return basis.

Ethical considerations: The ethical policy broadly follows that of the University of Bath. The trustees have precluded direct investment in tobacco. The trustees reserve the right to exclude companies that carry out activities contrary to their aims or from holding particular investments which damage the Charity's reputation.

The objectives are to be achieved by investing prudently in a broad range of equities, fixed interest securities and collective vehicles (like unit trusts) which are appropriately authorised.

Dividends and interest are paid away on a quarterly basis.

Summary of plans for the future

BIRD remains committed to funding research into rheumatic diseases, through pump-prime funding of around £80,000, depending on the quality of applications received. It will encourage clinicians to undertake research and early stage career researchers with their development through enhanced numbers of bursaries for conference attendance.

BIRD will continue to maintain and develop the education programme for healthcare professionals.

The Patient Engagement programme will continue to evolve, as digital offerings develop and ways to help patients get involved in research develop. The programme will also seek to help researchers to work with patients. Ongoing evaluation and patient input will shape the programme, through the patient research panel, the patient listening panel and through surveys and feedback.

The long-term intention remains to balance reliance on investment performance with more grant and donor fundraising, which itself requires a raised profile and clearer articulation of impact. BIRD will work on a strategy to achieve that during the year ahead.

Next year BIRD will undertake a recruitment exercise for new Trustees and committee members as part of good succession planning.

As part of its 50th Anniversary in 2025 BIRD will maximise engagement with the public, patients and stakeholders.



Details of The Independent Examiner

Tom Case
Member of The Institute of Chartered
Accountants in England and Wales
20 Goodwood Way
Cepen Park South
Chippenham
Wiltshire
SN14 0SY

Statement of the Directors' and Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.



The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

Method of preparation of accounts - Small company provisions. The financial statements are set out on pages 16 to 35.

The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016)

These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 20 September 2024.

Professor Bernie Morley emeritus
Chair



I report to the Trustees on my examination of the financial statements of the charitable company on pages 15 to 34 for the year ended 31 March 2024 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW), and under the historical cost convention and the accounting policies set out on page 21.

Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 11, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

- a) examine the financial statements of the charity under Section 145 of the Act;
- b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

Basis of Independent Examiner's Statement and scope of work undertaken

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider



in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide.

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

Independent Examiner's Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

- The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;
- This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;
- and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-
- accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;
- the financial statements do not accord with those records; or

- the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination;
- have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:-

Tom Case - Independent Examiner

The Institute of Chartered Accountants in
England and Wales

20 Goodwood Way
Cepen Park South
Chippenham
Wiltshire SN14 0SY

This report was signed on 20 September 2024.

Statement of Financial Activities for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

	SORP Ref	Current Unrestricted Funds	Current Restricted Funds	Current Total Funds	Prior Total Funds
		2024 £	2024 £	2024 £	2023 £
Income & Endowments from:					
Donations & Legacies	A1	38,464	-	38,464	52,340
Charitable activities	A2	24,550	75	24,625	66,645
Investments	A4	43,797	-	43,797	44,462
Total income	A	106,811	75	106,886	163,447
Expenditure on:					
Charitable activities	B2	238,208	472	238,680	244,037
Total expenditure	B	238,208	472	238,680	244,037
Net gains/(losses) on investments	B4	246,833	-	246,833	(62,316)
Net income for the year		115,436	(397)	115,039	(142,906)
Transfers between funds	C	89	(89)	-	-
Net income after transfers	A-B-C	115,525	(486)	115,039	(142,906)
Net movement in funds		115,525	(486)	115,039	(142,906)
Reconciliation of funds:-					
	E				
Total funds brought forward		1,657,920	18,679	1,676,599	1,819,505
Total funds carried forward		1,773,445	18,193	1,791,638	1,676,599

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A Statement of Total Recognised Gains and Losses is included as a primary statement in these accounts.
All activities derive from continuing operations

The notes attached on pages 22 to 35 form an integral part of these accounts.

Statement of Financial Activities for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Analysis of prior year total funds as required by paragraph 4.2 of the SORP

	SORP Ref	Prior Year Unrestricted Funds 2023 £	Prior Year Restricted Funds 2023 £	Prior Year Total Funds 2023 £
Income & Endowments from:				
Donations & Legacies	A1	52,340	-	52,340
Charitable activities	A2	66,495	150	66,645
Other trading activities	A3	-	-	-
Investments	A4	44,462	-	44,462
Other	A5	-	-	-
Total income	A	163,297	150	163,447
Expenditure on:				
Raising funds	B1	-	-	-
Charitable activities	B2	243,443	594	244,037
Other	B3	-	-	-
Tax on surplus on ordinary activities	B3	-	-	-
Other taxation	B3	-	-	-
Total expenditure	B	243,443	594	244,037
Net gains/(losses) on investments	B4	(62,316)	-	(62,316)
Net income for the year		(142,462)	(444)	(142,906)
Transfers between funds	C	2,085	(2,085)	-
Net income after transfers		(140,377)	(2,529)	(142,906)
Net movement in funds		(140,377)	(2,529)	(142,906)
Reconciliation of funds:-				
	E			
Total funds brought forward		1,799,804	19,701	1,819,505
Total funds carried forward		1,659,427	17,172	1,676,599

All activities derive from continuing operations

A Statement of Total Recognised Gains and Losses is included in these accounts as a separate primary statement

The notes attached on pages 22 to 35 form an integral part of these accounts.

Statement of Financial Activities for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Statement of Total Recognised Gains and Losses for the year ended 31 March 2024

	2024 £	2023 £
(Deficit)/Surplus for the year :-		
Net excess of income over expenditure from operations before tax	(131,794)	(80,590)
Income from operations before tax in the Statement of Financial Activities	(131,794)	(80,590)
Realised (losses)/gains on investments	-	(710)
Surplus as shown in the Income and Expenditure account	(131,794)	(81,300)
Unrealised (losses)/gains on investments	246,833	(61,606)
Net Movement in funds before taxation	115,039	(142,906)
Funds generated in the year as shown on Statement of Financial Activities	115,039	(142,906)

Statement of Financial Activities for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Income and Expenditure Account for the year ended 31 March 2024 as required by the Companies Act 2006

	2024 £	2023 £
Income		
Income from operations	63,089	118,985
Realised gains/(losses) on investments	-	(710)
Investment income		
Income from investments, other than interest receivable	43,797	44,462
Gross income in the year before exceptional items	106,886	162,737
Gross income in the year including exceptional items	106,886	162,737
Expenditure		
Charitable expenditure, excluding depreciation and amortisation	237,788	243,311
Depreciation and amortisation	430	276
Governance costs	462	450
Total expenditure in the year	238,680	244,037
Net income before tax in the financial year	(131,794)	(81,300)
Tax on surplus on ordinary activities	-	-
Net income after tax in the financial year	(131,794)	(81,300)
Retained surplus for the financial year	(131,794)	(81,300)

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

The notes attached on pages 21 to 34 form an integral part of these accounts.

Balance Sheet as at 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

Balance Sheet as at 31 March 2024

	Note	SORP Ref	2024 £	2023 £
Fixed assets	A			
Tangible assets	9	A2	1,786	667
Investments held as fixed assets	10	A4	1,871,796	1,674,963
Total fixed assets			1,873,582	1,675,630
Current assets		B		
Debtors	12	B2	5,774	9,628
Cash at bank and in hand		B4	44,602	48,995
Total current assets			50,376	58,623
Creditors: amounts falling due within one year	13	C1	(132,320)	(57,654)
Net current assets			(81,944)	969
The total net assets of the charity			1,791,638	1,676,599
The total net assets of the charity are funded by the funds of the charity, as follows:-				
Restricted funds				
Restricted Revenue Funds	17	D2	18,193	18,679
Unrestricted Funds				
Unrestricted Revenue Funds	17	D3	1,754,967	1,631,034
Designated Funds				
Designated Revenue Funds	17	D3	18,478	26,886
Total charity funds			1,791,638	1,676,599

The notes attached on pages 22 to 35 form an integral part of these accounts.

Balance Sheet as at 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA..

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 14.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006, applicable to companies subject to the small companies regime.

James Sherwin
Trustee and Chair of the Finance Committee
Approved by the board of trustees on
20 September 2024



1 Accounting policies

Policies relating to the production of the accounts.

Basis of preparation and accounting convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW), effective January 2016, and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Going Concern

The Trustees are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements. The Trustees are not aware of any material uncertainties about the charity's ability to continue as a going concern.

Risks and future assumptions

BIRD meets the definition of a public benefit entity under FRS102. Assets and liabilities are initially recognised at historical cost or transaction value unless stated in the relevant accounting policy note(s).

Policies relating to categories of income and income recognition.

Nature of income

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income

Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.

Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.

Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.

Income recognition

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity's assets or a reduction in its liabilities and only



when the charity has legal entitlement, the income is probable and can be measured reliably.

Dividends are accrued when the shareholder's right to receive payment is established.

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.

Income from legacies

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy are disclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities

Policies relating to expenditure on goods and services provided to the charity.

Recognition of liabilities and expenditure

A liability, and the related expenditure, is recognised when a legal or constructive obligation exists as a result of a past event, and when it is more likely than not that a transfer of economic benefits will be required in settlement, and when the amount of the obligation can be measured or reliably estimated..

Liabilities arising from future funding commitments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required to settle the obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increases in liabilities, and is decreased by the utilisation of any provision within the period, and reversed if any provision is no longer required. These movements are charged or credited to the respective funds and activities to which the provision relates.

Policies relating to assets, liabilities and provisions and other matters.

Fixed Asset Investments

Fixed asset investments in quoted shares, traded bonds, investment properties and similar investments are shown initially at cost upon acquisition and at their market value at the balance sheet date at the end of the



financial period. Investment properties are not depreciated.

Fixed asset investments in unlisted equities are shown at the balance sheet date at the best estimate of their market value, where practicable. Where valuation techniques are considered unreliable or where, in the opinion of the trustees, the costs outweigh the benefits to the users of the accounts, the investment is included at cost, and a review is undertaken at each year end as to whether the asset should be written down.

All gains on fixed asset investments, whether realised or unrealised, are included in row B4 of the Statement of Financial Activities.

Tangible fixed assets

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery	20 % reducing balance
---------------------	-----------------------

Stocks and work in progress

Stock is valued at the lower of cost and net realisable value.

Debtors

Debtors are measured at their recoverable amounts at the balance sheet date.

Creditors and provisions

Liabilities are recognised on the accruals basis in accordance with normal accounting principals, modified where necessary in

accordance with the guidance given in the SORP.

Financial instruments including cash and bank balances

Cash held by the charity is included at the amount actually held and counted at the year end. Bank balances, whether in credit or overdrawn, are shown at the amounts properly reconciled to the bank statements.

Fund Accounting

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

Designated funds are unrestricted funds earmarked by the Trustees for particular purposes.

Restricted funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal or as implied by law.

There are no endowment funds.

2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.



3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

4 Significance of financial instruments to the charity's position

There are no significant implications of financial instruments to the charity's financial position or performance.

5 Net surplus before tax in the financial year

The net surplus before tax in the financial year is stated after charging:-

Depreciation of owned fixed assets:-

2024	2023
£	£
£430	£ 276

Notes to the Accounts for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

6 Investment gains

	Current year Unrestricted Funds 2024	Current year Restricted Funds 2024	Current year Total Funds 2024	Prior Year Total Funds 2024
Realised gains/(losses)				
Listed investments	-	-	-	(710)
Unrealised gains /(losses) and writing down of carrying values				
Listed investments - Unrealised	246,833	-	246,833	(61,606)
Total unrealised gains/(losses) etc	246,833	-	246,833	(61,606)
Total realised and unrealised gains	246,833	-	246,833	(62,316)

All the gains and losses in the prior year was unrestricted.

Prior year

	Prior Year Unrestricted Funds 2023 £	Prior Year Restricted Funds 2023 £	Prior Year Total Funds 2023 £
Realised gains/(losses)			
Listed investments	(710)	-	(710)
Total realised gains/(losses)	(710)	-	(710)
Unrealised gains /(losses) and writing down of carrying values			
Listed investments - Unrealised	(61,606)	-	(61,606)
Total unrealised gains/(losses) etc	(61,606)	-	(61,606)
Total realised and unrealised gains	(62,316)	-	(62,316)

Notes to the Accounts for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

7 Staff costs and emoluments

<i>Labour costs</i>	2024 £	2023 £
Gross salaries, labour and related costs	133,060	119,611
	133,060	119,611

Neither the trustees nor any persons connected with them have received any remuneration from the charity or any related entity, either in the current or prior year.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

8 Remuneration and payments to Trustees and persons connected with them

No trustees or persons connected with them received any remuneration from the charity, or any related entity.

9 Tangible fixed assets

<i>Current Year</i>	Plant & Machinery	Motor Vehicles	Total
	£	£	£
Cost			
At 1 April 2023	11,940	-	11,940
Additions	1,549	-	1,549
At 31 March 2024	13,489	-	13,489
Depreciation			
At 1 April 2023	11,273	-	11,273
Charge for the year	430	-	430
At 31 March 2024	11,703	-	11,703
Net book value			
At 31 March 2024	1,786	-	1,786
At 31 March 2023	667	-	667

Notes to the Accounts for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

10 Investments held as fixed assets

	Investments in subsidiaries	Listed Investments	Other Classes of Investment	Total
	£	£	£	£
Carrying values of investments				
At 1 April 2023	2	1,674,961	-	1,674,963
Revaluation at 31 March 2024	-	246,833	-	246,833
Disposals	-	(50,000)	-	(50,000)
At 31 March 2024	2	1,871,794	-	1,871,796

11 Subsidiary companies

The name of the subsidiary undertaking is Bath Institute for Rheumatic Diseases Trading Limited, registered in England & Wales with company number 2602509.

The aggregate amount of the holding company's investment in its subsidiary is £2, which represents 100% of the issued ordinary share capital of the subsidiary. The subsidiary is controlled by the holding company by virtue of the power to appoint directors to the board of the subsidiary.

The subsidiary's activities relate to those of the holding company in that the subsidiary is a trading enterprise engaging in trades similar to the charitable activities of the holding company, and donates its entire taxable trading profit to the holding company by way of gift aid. The subsidiary has been dormant for the nine years ending 31st March 2024.

A summary of the unaudited financial statements of the subsidiary is :-

	2024 £	2023 £
Assets and Funds		
Aggregate amount of assets	(231)	(231)
Aggregate amounts of liabilities	(316)	(316)
Aggregate amount of funds	(547)	(547)

Profit and Loss

Net profit for the year before tax	-	-
Net profit for the year after tax and Gift Aid	-	-

Funds retained within charitable subsidiaries

	2024 £	2023 £
The funds retained within the trading subsidiary and included within the restricted funds in the notes to these accounts are:-	-	-

Notes to the Accounts for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

12 Debtors

	2024 £	2023 £
Trade Debtors	5,513	8,767
Payments and accrued income	261	861
	5,774	9,628

13 Creditors: amounts falling due within one year

	2024 £	2023 £
Trade creditors	42,542	14,325
Accruals	9,900	6,600
Other creditors	79,878	36,729
	132,320	57,654

14 Income and Expenditure account summary

	2024 £	2023 £
At 1 April 2023	1,738,205	1,819,505
Surplus after tax for the year	(131,794)	(81,300)
At 31 March 2024	1,606,411	1,738,205

15 No related party transactions

There were no transactions with related parties in the year.

Notes to the Accounts for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

16 Particulars of how particular funds are represented by assets and liabilities

At 31 March 2024	Unrestricted Funds £	Designated Funds £	Restricted Funds £	Total Funds £
Tangible Fixed Assets	1,786	-	-	1,786
Investments at valuation:-				
<i>Fixed asset investments</i>	1,871,796	-	-	1,871,796
Current Assets	13,705	18,478	18,193	50,376
Current Liabilities	(132,320)	-	-	(132,320)
	1,754,967	18,478	18,193	1,791,638
At 1 April 2023	Unrestricted Funds £	Designated Funds £	Restricted Funds £	Total Funds £
Tangible Fixed Assets	667	-	-	667
Investments at valuation:-				
<i>Fixed asset investments</i>	1,674,963	-	-	1,674,963
Current Assets	13,058	26,886	18,679	58,623
Current Liabilities	(57,654)	-	-	(57,654)
	1,631,034	26,886	18,679	1,676,599

17 Change in total funds over the year as shown in Note 16 , analysed by individual funds

	Funds brought forward from 2023 £	Movement in funds in 2024 See Note 18 £	Transfers between funds in 2024 See Note 19 £	Funds carried forward to 2025 £
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	1,631,034	115,436	8,497	1,754,967
Designated Revenue Funds	26,886	-	(8,408)	18,478
Total unrestricted and designated funds	1,657,920	115,436	89	1,773,445
Restricted funds:-				
Restricted - CRPS Conference	1,121	-	-	1,121
Restricted - Bone and Joint	14,145	-	-	14,145
Restricted - Arthritis Grand Challenge	67	-	(67)	-
Restricted - Metabolic Bone Disease	3,346	(397)	(22)	2,927
Total restricted funds	18,679	(397)	(89)	18,193
Total charity funds	1,676,599	115,039	-	1,791,638

Notes to the Accounts for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

18 Analysis of movements in funds over the year as shown in Note 17

	Income 2024 £	Expenditure 2024 £	Other Gains & Losses 2024 £	Movement in funds 2024 £
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	106,811	(238,208)	246,833	115,436
Restricted funds:-				
Restricted - Metabolic Bone Disease	75	(472)	-	(397)
	106,886	(238,680)	246,833	115,039

19 Details of transfers between

The transfers shown in note 17 above are:-	2024 £
To/(from) Unrestricted Revenue Funds in accordance with the accounting policy 'Accounting for capital grants and fixed asset funds'.	8,497
To/(from) Designated Revenue Funds	(8,408)
To/(from) Restricted Revenue Funds	(89)
Net transfers	-

20 The purposes for which the funds

Unrestricted and designated funds:-

Unrestricted Revenue Funds These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and , subject to charity legislation, are free from all restrictions on their use.

Designated Revenue Funds Funds specific for this purpose.

Restricted funds:-

Restricted Revenue Funds Funds specific for this purpose.

21 Ultimate controlling party

The charity is under the control of its legal members.
Every member of the charity is obliged to contribute such amount as may be required not exceeding £1 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.



22 Donations, Grants and Legacies

	Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current year Total Funds 2024 £	Prior Year Total Funds 2023 £
Donations and gifts from individuals				
Donations	38,462	-	38,462	52,301
Total donations and gifts from individuals	38,462	-	38,462	52,301
Legacies receivable				
Legacies receivable	2	-	2	39
Total legacies receivable	2	-	2	39

Total Donations, Grants and Legacies

Total Donations, Grants and Legacies	A1	38,464	-	38,464	52,430
---	-----------	---------------	----------	---------------	---------------

Notified of a share of the estate of Hedley John Stephens yet to be realised.

23 Income from charitable activities - Trading Activities

<i>Current year</i>	Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current year Total Funds 2023 £	Prior Year Total Funds £
2024				
Primary purpose and ancillary trading				
Education income	1,923	75	1,998	43,287
Other and recharged income	105	-	105	1,139
Service charges - BGPRT	17,558	-	17,558	17,561
Service charges - BRIT PACT	4,964	-	4,964	4,658
Total Primary purpose and ancillary trading	24,550	75	24,625	66,645

Not all the trading activities in the prior year were unrestricted

<i>Prior Year</i>	Prior year Unrestricted Funds 2023 £	Prior Year Restricted Funds 2023 £	Prior Year Total Funds 2023 £
Primary purpose and ancillary trading			
Education income	43,287	-	43,287
Other and recharged income	989	150	1,139
Service charges - BGPRT	17,561	-	17,561
Service charges - BRIT PACT	4,658	-	4,658
Total Primary purpose and ancillary trading	66,495	150	66,645



24 Total Income from charitable activities

<i>Current year</i>		Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current year Total Funds 2024 £	Prior Year Total Funds 2023 £
Total income from charitable trading		24,550	75	24,625	66,645
Total from charitable activities	A2	24,550	75	24,625	66,645

Not all the income in the prior year was unrestricted.
Income from charitable activities - Prior Year analysis

<i>Prior Year</i>	Prior year Unrestricted Funds 2023 £	Prior Year Restricted Funds 2023 £	Prior Year Total Funds 2023 £
Total income from charitable trading	66,495	150	66,645
	66,495	150	66,645

25 Investment income

	Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current Year Total Funds 2024 £	Prior Year Total Funds 2023 £
Dividend Income	43,797	-	43,797	44,462
Total investment income A4	43,797	-	43,797	44,462

26 Expenditure on charitable activities - Direct spending

	Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current Year Total Funds 2024 £	Prior Year Total Funds 2023 £
Labour costs - charitable activities	133,060	-	133,060	119,611
Education costs	7,269	472	7,741	42,273
PPE Project costs	2,344	-	2,344	8,545
Total direct spending	B2a	472	143,145	170,429

Not all the expenditure in the prior year was unrestricted.

Notes to the Accounts for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

27 Expenditure on charitable activities- Grant funding of activities

<i>Current Year</i>	Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current Year Total Funds 2024 £	Prior Year Total Funds 2023 £
Grants made to individuals	63,776	-	63,776	49,739
Total grantmaking costs B2c	63,776	-	63,776	49,739

28 Support costs for charitable activities

<i>Current Year</i>	Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current Year Total Funds 2024 £	Prior Year Total Funds 2023 £
Premises Expenses				
Rent	3,300	-	3,300	6,000
Administrative overheads				
Telephone, fax and internet	1,034	-	1,034	760
Stationery and printing	1,151	-	1,151	423
Marketing and promotion	14,926	-	14,926	5,307
Registration and licensing	1,622	-	1,622	1,068
IT support costs	2,380	-	2,380	1,867
Sundry expenses	-	-	-	720
Recharged expenses	72	-	72	1,189
Insurance	547	-	547	440
Trustees costs	177	-	177	-
Hospitality	472	-	472	-
Travel	20	-	20	67
Professional fees paid to advisors other than the auditor or examiner				
Accountancy fees other than examination or audit fees	4,033	-	4,033	3,660
Other legal and professional	1,017	-	1,017	1,526
Financial costs				
Bank charges	116	-	116	116
Depreciation	430	-	430	276
Total support costs	31,297	-	31,297	23,419

	Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Prior Year Total Funds 2023 £
Recharged expenses	595	594	1,189
Support costs before reallocation	22,825	594	23,419
Total support costs - Prior Year	22,825	594	23,419

Notes to the Accounts for the year ended 31 March 2024



Bath Institute for Rheumatic Diseases
Supporting arthritis research, education
and patient engagement

29 Other Expenditure - Governance costs

<i>Current Year</i>	Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current Year Total Funds 2024 £	Prior Year Total Funds 2023 £
Independent Examiner's fees	462	-	462	450
Total Governance costs	462	-	462	450

All the expenditure in the prior year was unrestricted.

30 Total Charitable expenditure

<i>Current Year</i>		Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current Year Total Funds 2024 £	Prior Year Total Funds 2023 £
Total direct spending	B2a	142,673	472	143,145	170,429
Total grantmaking costs	B2c	63,776	-	63,776	49,739
Total support costs	B2d	31,297	-	31,297	23,419
Total Governance costs	B2e	462	-	462	450
Total charitable expenditure B2		238,208	472	238,680	244,037

<i>Prior Year</i>		Prior year Unrestricted Funds 2023 £	Prior Year Restricted Funds 2023 £	Prior Year Total Funds 2023 £
Total direct spending	B2a	170,429	-	170,429
Total grantmaking costs	B2c	49,739	-	49,739
Total support costs	B2d	22,825	594	23,419
Total Governance costs	B2e	450	-	450
Total charitable expenditure B2		243,443	594	244,037



GRANTS AWARDED
FOR RESEARCH
£63,551



415
HEALTH
PROFESSIONALS
ATTENDING
TRAINING
SESSIONS



15
OPPORTUNITIES
TO PARTICIPATE IN
RESEARCH
OFFERED TO
PATIENTS



90%
OF THOSE
ATTENDING THE
RESEARCH
SHOWCASE SAID
THEY WERE MORE
LIKELY TO GET
INVOLVED IN
RESEARCH



20,000
LISTENS TO
PODCASTS

**Overall, the charity's
beneficiaries: scientific
academia and patients,
carers and their
families benefitted from
better understanding of
rheumatic diseases and
their treatment, thereby
contributing to the
alleviation of suffering.**



Bath Institute for Rheumatic Diseases

Supporting arthritis research, education
and patient engagement

**ANNUAL REPORT
AND
ACCOUNTS
*31 March 2024***

Company Registration Number 02908933
Charity Registration Number 1040650